As nicotine pouches continue to emerge within tobacco harm reduction discussions, policymakers are increasingly faced with a fundamental question: how should the health risks of these products be assessed? Public debate often reduces the issue to a simple question of whether nicotine pouches are “safe” or “unsafe.” While understandable, this framing overlooks how modern toxicology…
The rapid emergence of oral nicotine pouches has presented policymakers with a familiar challenge. Innovation is moving faster than legislation, forcing regulators to determine how new products fit within legal frameworks that were largely designed for traditional tobacco products decades ago. A recent editorial published in Addiction, “Novel Product, Familiar Challenges: Navigating Uncertainty in Oral…
Public health discussions surrounding problematic drug use often focus on overdose prevention, infectious diseases, mental health, and access to treatment services. Yet one of the most significant contributors to illness and premature mortality among people who use drugs frequently receives far less attention: smoking. A recent briefing paper from the Global State of Tobacco Harm…
Nicotine should be regulated proportionately to its risks and in a manner that accelerates the decline of combustible smoking. It should not be governed through sweeping “endgame” narratives that treat all nicotine products as though they occupy the same place on the risk spectrum. Recent interventions from both The Guardian and the Government of Palau…
A Growing Divide in European Nicotine Policy The European Union is approaching a critical moment in nicotine regulation. As policymakers prepare for major revisions to the Tobacco Excise Directive (TED), the Tobacco Products Directive (TPD), and wider tobacco control legislation, a fundamental disagreement has emerged within European institutions. At the heart of the debate is…
Understanding the Findings and Their Policy Implications As nicotine pouches continue to emerge in markets around the world, regulators face a familiar challenge: how should policymakers respond when new products enter the market before dedicated regulatory frameworks are fully established? A recent study examining nicotine pouches sold in Karachi has contributed new data to this…
A New Direction in European Nicotine Policy Over the past decade, Europe has been at the centre of some of the world’s most significant debates on tobacco harm reduction. Products such as nicotine pouches, vaping products, and heated tobacco products emerged as alternatives to combustible cigarettes and were often discussed through the lens of risk…
As governments consider how to regulate nicotine pouches, one model is becoming increasingly important: treating oral nicotine products not as general consumer goods, but as medicines, natural health products, poisons, or pharmaceutical-style nicotine replacement therapies. This approach is most clearly visible in Canada, where Zonnic has become the leading example of a nicotine pouch authorised…
While the European Union does not currently have a dedicated framework for modern nicotine products, several jurisdictions have already developed regulatory approaches that provide useful reference points for policymakers. These examples demonstrate that nicotine products can be regulated through frameworks that balance consumer protection, product oversight, youth safeguards, and adult access without relying solely on…
The global nicotine landscape continues to evolve at a rapid pace. Over the past decade, regulators have focused primarily on traditional tobacco products, vaping devices, heated tobacco products, nicotine pouches, and synthetic nicotine. However, a new category is beginning to attract attention from policymakers, scientists, and public health stakeholders: nicotine analogs. While nicotine analogs remain…